Phase 3 Clinical Trials With Primary Completion Dates in January 2022

This is a list of Phase 3 trials with primary completion dates in January 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ADILAdial Pharmaceuticals, Inc.2022-01-01Phase 3NCT04101227Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms
ARNAArena Pharmaceuticals, Inc.2022-01-01Phase 3NCT03945188Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
CHHEChina Health Industries Holdings, Inc.2022-01-01Phase 3NCT05159947SPT-07A Injection in Patients With Acute Ischemic Stroke (AIS): A Phase III Clinical Trial
CORTCorcept Therapeutics Incorporated2022-01-01Phase 3NCT04329949Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
CYDYCytoDyn Inc.2022-01-01Phase 3NCT04901676Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia
FGENFibroGen, Inc.2022-01-01Phase 3NCT03263091Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden
MRNSMarinus Pharmaceuticals, Inc.2022-01-01Phase 3NCT04391569RAndomized Therapy In Status Epilepticus
OBSVObsEva SA2022-01-01Phase 3NCT03992846Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
VRNAVerona Pharma plc2022-01-01Phase 3NCT04542057A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
ZGNXZogenix, Inc.2022-01-01Phase 3NCT02823145An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome